Ekso Bionics Details 97% Dilutive Reverse Merger, Pivots to AI Cloud as "ChronoScale"

summarizeSummary

This filing provides full details of the reverse merger where Ekso Bionics will acquire Applied Digital Cloud Corporation, resulting in approximately 97% dilution for existing shareholders and a complete pivot to an AI cloud computing business under the new name "ChronoScale Corporation."

check_boxKey Events

• Reverse Merger Finalized

  Ekso Bionics will acquire Applied Digital Cloud Corporation (Cloud) in a reverse merger, becoming "ChronoScale Corporation." This follows the preliminary information statement filed on 2026-03-20.

• Massive Shareholder Dilution

  Existing Ekso Bionics shareholders will collectively own approximately 3% of the combined entity, reflecting a 97% dilution.

• Strategic Business Pivot

  The company's focus shifts entirely from exoskeleton technology to AI cloud computing, marking a complete change in business model.

• New Capital Infusion

  Applied Digital will invest at least $15 million in the combined company through an equity financing, providing critical liquidity and addressing the company's prior 'going concern' warning.

auto_awesomeAnalysis

This PRER14C filing provides the definitive terms of the previously announced reverse merger, where Ekso Bionics will acquire Applied Digital Cloud Corporation (Cloud) and rename itself "ChronoScale Corporation." This transaction fundamentally alters the company's business from medical exoskeletons to AI cloud computing. Existing shareholders will face approximately 97% dilution, retaining only about 3% ownership in the combined entity. The deal includes a crucial $15 million equity financing from Applied Digital, which addresses Ekso's prior "going concern" warning and provides necessary liquidity. The new board will be predominantly controlled by Applied Digital's designees, signifying a complete change in corporate governance and strategic direction. This is a highly significant, thesis-altering event with substantial negative implications for current shareholder value due to the extreme dilution.